1. US Food and Drug Administration (FDA). Expedited programs for serious conditions – drugs and biologics. Draft Guid Ind. 2014. 2014. https://www.fda.gov/media/86377/download.
2. When can intermediate outcomes be used as surrogate outcomes?;DeMets;JAMA,2020
3. Surrogate endpoints and FDA's accelerated approval process;Fleming;Health Aff,2005
4. US Food and Drug Administration (FDA). US Food and Drug Administration (FDA). CDER Drug and biologic accelerated approvals based on a surrogate endpoint. 2020. https://www.fda.gov/media/151146/download.
5. US Food and Drug Administration (FDA). Drugs@FDA: FDA-Approved drugs. 2021. https://www.accessdata.fda.gov/scripts/cder/daf/.